Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Roy M FleischmannRicardo Blanco-AlonsoStephen HallGlen T D ThomsonFilip E Van den BoschCristiano ZerbiniLouis BessetteJeffrey EnejosaYihan LiYanna SongRyan DeMasiIn-Ho SongPublished in: Annals of the rheumatic diseases (2020)
These observations support a treat-to-target strategy, in which patients who fail to respond initially (or do not achieve sufficient response) are switched to a therapy with an alternate mechanism of action and experience improved outcomes. No new safety findings were observed despite immediate switch without washout.